Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 332 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 332 shares of BeOne Medicines stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04. Following the completion of the sale, the senior vice president directly owned 101 shares of the company’s stock, valued at approximately $31,382.72. The trade was a 76.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88.
• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total transaction of $102,300.00.

BeOne Medicines Stock Down 3.7%

ONC traded down $11.35 during mid-day trading on Friday, reaching $293.27. 269,684 shares of the stock were exchanged, compared to its average volume of 254,986. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a market capitalization of $32.18 billion, a PE ratio of 65.61 and a beta of 0.50. The company has a 50 day moving average price of $300.53 and a two-hundred day moving average price of $321.93. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $227.05 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.3 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on ONC shares. Barclays boosted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Wolfe Research started coverage on BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective for the company. Leerink Partners boosted their price objective on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the stock from $420.00 to $290.00 in a report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $389.15.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital International Investors lifted its position in BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after buying an additional 67,808 shares during the period. Siren L.L.C. lifted its position in BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after buying an additional 7,010 shares during the period. Morgan Stanley lifted its position in BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after buying an additional 84,367 shares during the period. Bank of America Corp DE lifted its position in BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after buying an additional 65,763 shares during the period. Finally, Candriam S.C.A. lifted its position in BeOne Medicines by 31.7% during the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.